Pharmaceutical and Analytical Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.
Analyst. 2009 Jul;134(7):1405-15. doi: 10.1039/b821836f. Epub 2009 Mar 31.
Robust NIR transmission spectroscopic methods have been developed for determination of content uniformity (CU) of pharmaceutical products with a complex tablet matrix. The tablets of interest, formulated with eight components with active drug load of approximately 30% (w/w), are non-film coated, embossed, and round with thickness values of 3.6 and 5.6 mm, for the 125 and 500 mg dosage strength, respectively. The calibration data set contained seven laboratory scale batches of tablets with concentration range of active pharmaceutical ingredients (API) varying from 85 to 115% relative to label claim (LC) as well as four full scale production batches of tablets that included the natural physical variability of tablets. The reference concentration values were established by a high performance liquid chromatographic method. Partial least-squares (PLS) regression method was used to generate the calibration models. The root mean squared error of calibration for 125 and 500 mg was 1.6 and 1.5% in LC, respectively. The calibration models were validated in terms of measurement accuracy, repeatability, precision, robustness and transferability. Robustness assessment involved challenging the model with tablets incorporating variations in hardness, excipient vendors, excipient content and excipient particle size. The methods exhibited excellent measurement accuracy based on 87 batches (ten tablets for each batch) evaluated. The transferability of the developed NIR methods was demonstrated by comparing the NIR CU results associated with the same set of tablets scanned at the development site with those scanned at the production site. The result indicates that the NIR method can be used as a suitable alternative to the HPLC method for rapid tablet CU release test in pharmaceuticals.
已经开发出了稳健的近红外透射光谱方法,用于测定具有复杂片剂基质的药物产品的含量均匀度(CU)。所关注的片剂由八种成分组成,活性药物负载约为 30%(w/w),无薄膜包衣,压花,呈圆形,厚度值分别为 3.6 和 5.6 毫米,分别用于 125 和 500 毫克的剂量强度。校准数据集包含七个实验室规模批次的片剂,活性药物成分(API)的浓度范围从 85%到 115%相对标签声称(LC)以及四个全规模生产批次的片剂,其中包括片剂的自然物理变异性。参考浓度值通过高效液相色谱法确定。偏最小二乘(PLS)回归方法用于生成校准模型。125 和 500 毫克的校准均方根误差分别为 LC 的 1.6%和 1.5%。校准模型在测量准确性、重复性、精密度、稳健性和可转移性方面进行了验证。稳健性评估涉及用硬度、赋形剂供应商、赋形剂含量和赋形剂粒径变化的片剂挑战模型。该方法基于评估的 87 批(每批 10 片)片剂表现出出色的测量准确性。通过比较在开发现场扫描的同一组片剂的 NIR CU 结果与在生产现场扫描的结果,证明了所开发的 NIR 方法的可转移性。结果表明,NIR 方法可以作为 HPLC 方法的合适替代品,用于药物的快速片剂 CU 释放测试。